Vancouver, Canada – One year of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) was associated with significant improvements in work productivity and daily activities among people with cystic fibrosis (CF), according to a real-world study conducted in Canada. The improvements were linked to better lung function, enhanced physical functioning, fewer respiratory symptoms, and...

Lund, Sweden  –  Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first safety cohort of three patients enrolled under the amended protocol has successfully completed the 6-week safety evaluation period in the European phase Ib/II proof-of-concept study evaluating tasquinimod in patients with myelofibrosis (HOVON172 MF, the TasqForce study). In...

SAN DIEGO, Calif. — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. The...